A review in Genes & Diseases says robust non-clinical safety assessment is critical for CRISPR-based gene therapies. It highlights genotoxic, delivery, and immunological risks and recommends risk-based development programs.
The FDA has issued draft guidance creating a "Plausible Mechanism Framework" to accelerate approval of individualized therapies for ultra-rare diseases where traditional clinical trials are not feasible. The guidance focuses on gene editing and RNA-based treatments targeting specific genetic abnormalities.
Scientists have developed multiple breakthrough delivery systems for gene editing and mRNA therapies, including a simple amino acid supplement that increases delivery 20-fold and a CRISPR gene drive that reverses antibiotic resistance in bacterial populations.
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
